Element Biosciences
Element Biosciences is advancing the future of drug discovery by enabling high-dimensional multiomic analysis through its next-generation AVITI24™ platform. Founded in 2017, Element is committed to empowering researchers with flexible, accessible, and high-performance sequencing technologies.
The AVITI24 platform integrates genomic, transcriptomic, proteomic, and cytoprofiling data into a single workflow—delivering a comprehensive view of cellular systems at single-cell resolution. Powered by Element’s proprietary Avidite™ chemistry, AVITI24 offers exceptional data quality, cost efficiency, and scalability to accelerate biomarker discovery, target validation, and therapeutic development.
With a mission to remove barriers to discovery, Element is helping scientists generate deeper insights into biology and uncover new possibilities for improving human health.
